People who take popular weight loss drugs like Ozempic can have serious side effects and new research says stopping them can also cause problems. Now that millions of people have successfully lost weight using them,

Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, rates of bariatric surgeries dropped by 25%, while prescriptions for weight-loss drugs more than doubled.

Ozempic and related GLP-1 drugs have taken Europe and North America by storm and have quickly become the darling of the weight loss world.

Medically reviewed by Danielle Weiss, MD After losing extra pounds on Ozempic (semaglutide), some are finding themselves dealing with an unexpected issue, what's become known as "Ozempic breasts." This possible side effect of glucagon-like peptide 1 (GLP-1) agonist medication users like Ozempic,

Researchers at the University of Copenhagen have developed a new weight-loss drug that may surpass the effectiveness of Ozempic. This new drug stimula

A recent study found semaglutide – the drug known as Ozempic – can improve knee pain in people with obesity and osteoarthritis.

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs Ozempic and Wegovy. Novo Nordisk, the manufacturer of both, recently shared that CagriSema may lead to 10 percent more weight loss than Wegovy.

A new, better Ozempic? Scientists from the University of Copenhagen say they have developed a drug that decreases appetite while increasing calorie burning — without any signs of nausea. “While GLP-1-based therapies have revolutionized patient care for obesity and Type 2 diabetes,